U.S. Officials announced plans to end a long-standing duty-free exemption for Canadian goods entering the U.S. Via the postal system. The change, set to take effect in 2025, will remove the $800 de minimis exemption, affecting the cost of Canadian pharmaceuticals and other products.
The policy shift follows a presidential order aimed at adjusting trade practices between the U.S. And Canada. The exemption, which allowed small shipments to enter duty-free, has been in place for decades. With its removal, Canadian goods will face standard import duties, potentially increasing prices for consumers.
The decision has raised concerns among Canadian businesses and healthcare providers. Many rely on the exemption to keep medication costs low. Industry representatives warn that the change could lead to higher healthcare expenses for Americans and reduce the competitiveness of Canadian pharmaceuticals in the U.S. Market.
The policy change is part of broader U.S. Efforts to reform trade agreements and streamline customs procedures. It reflects ongoing tensions over trade rules and economic influence between the two nations.
Historically, the duty-free exemption was introduced to encourage cross-border trade and support Canadian industries. However, it has also been criticized for allowing some goods to bypass standard tariffs. The new rule marks a significant shift in how the U.S. Regulates imports from Canada.
